严重神经发育障碍疗法开发商GRIN Therapeutics宣布完成1.4亿美元D轮融资-动脉网

GRIN Therapeutics and Angelini Pharma Enter into Exclusive Collaboration to Develop and Commercialize Radiprodil Outside North America

CISION 等信源发布 2025-05-27 20:30



可切换为仅中文







GRIN also announces closing of

GRIN还宣布了关闭

$140 million

1.4亿美元

Series D financing, including a

D轮融资，包括一个

$65 million

6500万美元

strategic equity investment from Angelini Pharma and

来自Angelini Pharma的战略股权投资和

$75 million

7500万美元

from existing investor Blackstone Life Sciences

来自现有投资者黑石生命科学

Collaboration combines Angelini Pharma's global reach and focus on complex neurological disorders with GRIN's expertise and capabilities in developing and advancing precision therapeutics for neurodevelopmental disorders

协作结合了Angelini Pharma的全球影响力和对复杂神经系统疾病的专注，以及GRIN在开发和推进神经发育障碍精准治疗方面的专业知识和能力。

Under terms of the collaboration, GRIN is to receive

根据合作协议的条款，GRIN将收到

$50 million

5000万美元

upfront, and is eligible to receive up to

预先，并有资格获得最多

$520 million

5.2亿美元

in milestones and tiered royalties in addition to shared development costs

除了共同的开发成本外，还包括里程碑和分级特许权使用费

GRIN will continue to lead global development and retains exclusive rights for radiprodil in

GRIN 将继续领导全球开发，并保留 radiprodil 的独家权利。

the United States

美国

，

Canada

加拿大

, and

，以及

Mexico

墨西哥

Funding from both transactions will support ongoing operations including planned global pivotal Phase 3 trial for radiprodil in the treatment of GRIN-related neurodevelopmental disorder in 3Q 2025

两项交易的融资将支持持续的运营，包括计划在2025年第三季度进行的radiprodil治疗GRIN相关神经发育障碍的全球关键性3期临床试验。

NEW YORK

纽约

and

和

ROME

罗马

，

May 27, 2025

2025年5月27日

/PRNewswire/ -- GRIN Therapeutics, Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, and Angelini Pharma, part of the privately owned Angelini Industries, today announced a collaboration for the development and commercial rights outside of

/PRNewswire/ -- GRIN Therapeutics, Inc.，一家致力于开发治疗严重神经发育障碍疗法的领导者，与隶属于私人拥有的Angelini Industries的Angelini Pharma今天宣布了一项合作，涉及除……以外地区的开发和商业权利。

North America

北美

of GRIN Therapeutic's investigational drug radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders.

GRIN治疗公司正在研究的试验药物radiprodil，目前正用于多种罕见遗传性癫痫和神经发育障碍的研究。

GRIN Therapeutics also announced the closing of its

GRIN Therapeutics 还宣布了其

$140 million

1.4亿美元

Series D financing with investment by Angelini Pharma and Blackstone Life Sciences. Together, the two transactions highlight a significant total near-term commitment of

D轮融资由Angelini Pharma和黑石生命科学投资。这两笔交易共计体现了显著的近期承诺总额。

$115 million

1.15亿美元

from Angelini Pharma, which includes a

来自Angelini Pharma，其中包括一个

$65 million

6500万美元

strategic equity investment and a

战略股权投资和

$50 million

5000万美元

upfront payment related to the collaboration. Existing GRIN Therapeutics investor Blackstone Life Sciences contributed

与合作相关的预付款。现有的GRIN Therapeutics投资者黑石生命科学（Blackstone Life Sciences）贡献了力量。

$75 million

7500万美元

to the Series D financing round. Jacopo Andreose, PhD, CEO of Angelini Pharma, will join GRIN's Board of Directors.

D轮融资轮次。Angelini Pharma的首席执行官Jacopo Andreose博士将加入GRIN的董事会。

'We are very pleased to close this financing round and to welcome Angelini Pharma—an ideal partner whose engagement reflects the significant value we've built around the radiprodil program in a relatively short period,' said

“我们非常高兴完成此轮融资，并欢迎Angelini Pharma——一个理想的合作夥伴，其参与反映了我们在相对较短的时间内在radiprodil项目上建立的重要价值，”

Bruce Leuchter

布鲁斯·勒切特

, MD, President & CEO of Neurvati Neurosciences and GRIN Therapeutics. 'This strategic collaboration marks an important point of validation for GRIN Therapeutics, the clinical data generated to date, and the potential of radiprodil as the first approved treatment for patients with GRIN-related neurodevelopmental disorder (GRIN-NDD)—a population with urgent unmet need.

，医学博士，Neurvati Neurosciences 和 GRIN Therapeutics 总裁兼首席执行官。“这一战略协作标志着对 GRIN Therapeutics、迄今为止生成的临床数据以及 radiprodil 作为首个获批用于治疗 GRIN 相关神经发育障碍（GRIN-NDD）患者的潜力的重要验证点——这是一个存在迫切未满足需求的群体。”

We are also deeply grateful for the continued support and commitment of Blackstone Life Sciences, whose partnership has been instrumental in advancing our efforts. With this momentum, we are well-positioned to move radiprodil into pivotal trials and take an important step toward delivering a novel therapeutic option to patients and families.'.

我们对黑石生命科学的持续支持和承诺深表感谢，他们的合作对推动我们的工作至关重要。有了这一势头，我们已经准备好将radiprodil推进到关键试验阶段，并在为患者和家庭提供一种新的治疗选择方面迈出重要的一步。

'Our strategic collaboration with GRIN Therapeutics, including our participation in this Series D financing and in-licensing deal for radiprodil, reflects our dedication to advancing highly innovative treatments in brain health, building on our deep therapeutic expertise in neurology and psychiatry' said Jacopo Andreose, PhD, CEO of Angelini Pharma.

“我们与GRIN治疗学公司的战略协作，包括我们参与此次D轮融资以及radiprodil的授权引进协议，体现了我们致力于推进大脑健康领域的高度创新疗法，依托我们在神经病学和精神病学方面的深厚治疗专长，”Angelini Pharma首席执行官Jacopo Andreose博士说道。

'We see radiprodil as an opportunity to address the substantial unmet medical need of people living with GRIN-NDD and potentially other rare pediatric neurological diseases. We look forward to working closely with the team at GRIN Therapeutics to help bring this promising therapy to patients around the world.'.

“我们认为radiprodil是解决GRIN-NDD患者以及潜在其他罕见儿童神经疾病患者未满足医疗需求的一个机会。我们期待与GRIN Therapeutics团队紧密合作，帮助将这一有前景的疗法带给世界各地的患者。”

'Angelini Pharma is a leading international pharmaceutical company and we are thrilled to have their backing, partnership and commitment to the further growth of GRIN Therapeutics and development of radiprodil,' said

“Angelini Pharma是一家领先的国际制药公司，我们非常高兴得到他们的支持、合作，并承诺进一步推动GRIN Therapeutics的发展和radiprodil的开发，”

Kiran Reddy

基兰·雷迪

, MD, Senior Managing Director, Blackstone Life Sciences. 'The team's rapid progress with radiprodil—achieving multiple regulatory designations and advancing toward a pivotal Phase 3 trial— is very promising and today's milestone also validates the ability of Neurvati's model to efficiently develop high-impact neuroscience therapies.'.

医学博士，黑石生命科学高级董事总经理。 “团队在radiprodil方面的快速进展——获得多项监管指定并迈向关键的第三阶段试验——非常有希望，而且今天的里程碑也验证了Neurvati模型高效开发高影响力神经科学疗法的能力。”

Radiprodil is a targeted, selective, and potent negative allosteric modulator of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor. NMDA receptors are crucial for synaptic transmission, cognition and seizures. Several NDDs and epilepsy syndromes are associated with either genetic mutations or overactivation of NMDA receptors..

Radiprodil 是一种靶向、选择性和强效的 N-甲基-D-天冬氨酸 (NMDA) 受体 GluN2B 亚基的负变构调节剂。NMDA 受体对于突触传递、认知和癫痫发作至关重要。多种神经发育障碍 (NDD) 和癫痫综合征与 NMDA 受体的基因突变或过度激活有关。

Radiprodil has received multiple regulatory designations, including Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with GRIN-NDD with gain-of-function (GoF) variants. Additionally, radiprodil has been granted FDA Orphan Drug designation, rare pediatric disease designation, European Medicines Agency (EMA) Priority Medicines (PRIME) designation, and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use (CHMP) for the treatment of GRIN-NDD.

Radiprodil 已获得多项监管指定，包括美国食品药品监督管理局（FDA）授予的用于治疗与 GRIN-NDD 相关的癫痫发作（具有功能获得性（GoF）变异）的突破性疗法认定。此外，Radiprodil 还获得了 FDA 的孤儿药认定、罕见儿科疾病认定、欧洲药品管理局（EMA）的优先药物（PRIME）认定，以及 EMA 人用药品委员会（CHMP）对 GRIN-NDD 治疗的孤儿药认定的积极意见。

The company remains on track to initiate a global, pivotal Phase 3 clinical trial for radiprodil in GRIN-NDD in the third quarter of 2025. Additionally, an ongoing open-label Phase .

公司仍有望在 2025 年第三季度启动 radiprodil 针对 GRIN-NDD 的全球关键性 3 期临床试验。此外，一项正在进行的开放标签 2 期试验。

/2a study, known as the Astroscape trial, is evaluating radiprodil in patients with tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II.

/2a期研究，即Astroscape试验，正在评估radiprodil在结节性硬化症（TSC）和局灶性皮质发育不良（FCD）II型患者中的效果。

Under the terms of the agreement, GRIN Therapeutics will continue to lead global development and retain exclusive rights for radiprodil in

根据协议条款，GRIN Therapeutics 将继续领导全球开发，并保留 radiprodil 的独家权利。

the United States

美国

，

Canada

加拿大

, and

，以及

Mexico

墨西哥

. Angelini Pharma will receive exclusive rights to commercialize radiprodil in the rest of the world. GRIN Therapeutics will receive an upfront payment of

Angelini Pharma将获得在全球其他地区商业化radiprodil的独家权利。GRIN Therapeutics将获得一笔预付款。

$50 million

5000万美元

, and the parties will share certain clinical development costs for radiprodil. Additionally, GRIN Therapeutics may receive up to an additional

，并且双方将分担雷迪波迪尔的某些临床开发成本。此外，GRIN治疗公司可能还会获得高达额外的

$520 million

5.2亿美元

based on achieving certain development, regulatory and sales milestones. GRIN Therapeutics is also eligible to receive tiered royalties based on global sales as well as payments from any future sublicense transactions outside of Europe.

基于实现某些开发、监管和销售里程碑，GRIN治疗学公司还有资格获得基于全球销售额的分级特许权使用费，以及来自欧洲以外任何未来转授权交易的付款。

'Our strategic collaboration with Angelini Pharma shows how global partnerships can play an important role in advancing our business strategy at Neurvati, which is purpose-built to identify, advance, and unlock the potential of promising neuroscience assets through focused, mid-to-late stage development,' said Dr.

“我们与Angelini Pharma的战略合作展示了全球合作伙伴关系如何在推进Neurvati的业务战略中发挥重要作用，该战略旨在通过专注的中后期开发，识别、推动并释放有前景的神经科学资产的潜力，”博士表示。

Leuchter, adding, 'We are also very pleased to welcome Jacopo Andreose to our Board of Directors. His deep expertise in global drug development and commercialization will be a significant advantage for us as we progress radiprodil through Phase 3 development and prepare for potential regulatory approvals worldwide.'.

勒赫特补充道：“我们非常高兴欢迎雅各布·安德烈奥塞加入我们的董事会。他在全球药物开发和商业化方面的深厚专业知识将为我们推进拉迪普罗迪尔的三期开发并为潜在的全球监管审批做准备提供重要优势。”

About Radiprodil

关于Radiprodil

Radiprodil is an investigational, potent negative allosteric modulator selectively targeting the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor, for the treatment of GRIN-related neurodevelopmental disorder (GRIN-NDD). It has been awarded Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations by the U.S.

Radiprodil 是一种研究性、强效的负变构调节剂，选择性靶向 N-甲基-D-天冬氨酸 (NMDA) 受体的 GluN2B 亚基，用于治疗 GRIN 相关神经发育障碍 (GRIN-NDD)。它已被美国授予突破性疗法、孤儿药和罕见儿科疾病资格认定。

Food and Drug Administration as well as Priority Medicines (PRIME) designation by the European Medicines Agency (EMA) and a positive opinion for orphan designation from the EMA Committee for Medicinal Products for Human Use (CHMP). The planned global Phase 3 trial for radiprodil for GRIN-NDD will aim to evaluate the impact of a targeted treatment on core aspects of the disease, including seizures, behavioral abnormalities and functional outcomes.

美国食品药品监督管理局以及欧洲药品管理局（EMA）的优先药物（PRIME）指定和EMA人类用药委员会（CHMP）对孤儿药认定的积极意见。计划中的全球第三阶段试验将评估radiprodil对GRIN-NDD的影响，针对疾病的核心方面，包括癫痫发作、行为异常和功能结果。

Radiprodil is also being developed for the treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. The Astroscape trial (ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase .

Radiprodil 还在开发用于治疗结节性硬化症复合体（TSC）和局灶性皮质发育不良（FCD）II型。Astroscape 试验（ClinicalTrials.gov 标识符：NCT06392009）是一项正在进行的、开放标签的第阶段试验。

/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II.

评估radiprodil在TSC或FCD II型患者中的安全性、耐受性、药代动力学（PK）和潜在疗效的2a期临床试验。

About GRIN Therapeutics

关于GRIN治疗学

GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers. Late last year,

GRIN Therapeutics 致力于研究和开发针对儿童神经发育障碍的精准疗法，旨在为患者和护理人员带来希望。去年年底，

GRIN Therapeutics reported promising topline data

GRIN Therapeutics报告了令人鼓舞的顶线数据

from a Phase

来自一个阶段

/2a clinical trial (the Honeycomb Trial, ClinicalTrials.gov NCT identifier: NCT05818943) evaluating radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD) in patients with gain-of-function (GoF) variants, leading to the decision to advance to a global Phase 3 trial. The company has an additional ongoing clinical trial to evaluate radiprodil for the potential treatment of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II.

/2a期临床试验（Honeycomb试验，ClinicalTrials.gov NCT标识符：NCT05818943）评估了radiprodil在GRIN相关神经发育障碍（GRIN-NDD）中针对功能获得型（GoF）变异患者的效果，这一结果促成了进入全球3期临床试验的决定。该公司还有另一项正在进行的临床试验，评估radiprodil用于治疗结节性硬化症（TSC）和局灶性皮质发育不良（FCD）II型的潜力。

GRIN Therapeutics is an affiliate of Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences. For more information, please visit .

GRIN Therapeutics 是 Blackstone Life Sciences 旗下投资组合公司 Neurvati Neurosciences 的关联公司。欲了解更多信息，请访问。

www.grintherapeutics.com

About Neurvati Neurosciences

关于Neurvati神经科学

Neurvati Neurosciences, a portfolio company of Blackstone Life Sciences, identifies and advances the development of high-potential drug candidates across the neuroscience landscape. Neurvati employs a collaborative model that establishes fit-for-purpose affiliate companies, aligning dedicated resources with long-term strategic capital to catalyze innovative treatment options in areas of unmet need.

Neurvati Neurosciences是黑石生命科学旗下的一家投资组合公司，致力于在神经科学领域识别并推动高潜力药物候选品的开发。Neurvati采用协作模式，建立符合特定需求的附属公司，将专用资源与长期战略资本相结合，以加速在未满足需求的领域催化创新治疗方案。

Neurvati's team of experienced operators and drug developers seeks opportunities to challenge current treatment paradigms and make a difference for patients suffering from a wide range of neurological and psychiatric disorders. For more information, please visit .

Neurvati的资深运营者和药物开发团队致力于寻找机会挑战当前的治疗模式，为患有各种神经和精神疾病的患者带来改变。欲了解更多信息，请访问。

www.neurvati.com

About Angelini Pharma

关于Angelini Pharma

Angelini Pharma is an international pharmaceutical company, part of the privately owned multi-business Angelini Industries. The Company researches, develops and commercializes health solutions with a focus on the areas of Brain Health, including Mental Health and Epilepsy, and Consumer Health. Founded in .

Angelini Pharma是一家国际制药公司，隶属于私营多元业务的Angelini Industries。公司专注于研究、开发和商业化健康解决方案，重点关注大脑健康（包括心理健康和癫痫）以及消费者健康领域。公司成立于。

Italy

意大利

at the beginning of the 20th century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are marketed in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information about Angelini Pharma please visit .

二十世纪初，Angelini Pharma 直接在 20 个国家开展业务，雇用超过 3,000 名员工。其产品通过与领先的国际制药集团的战略联盟在 70 多个国家销售。有关 Angelini Pharma 的更多信息，请访问。

https://www.angelinipharma.com

。

About Angelini Industries

关于 Angelini Industries

Angelini Industries is a multinational industrial group founded in Ancona in 1919 by

安吉里尼工业集团是一家跨国工业集团，1919年由在安科纳创立。

Francesco Angelini

弗朗切斯科·安杰利尼

. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over

如今，Angelini Industries代表了一个稳固且多元化的工业实体，在全球21个国家开展业务，拥有约5800名员工，营收超过

2 billion euros

20亿欧元

, generated in the health, industrial technology, and consumer goods sectors. A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.

，生成于健康、工业技术和消费品领域。针对性的投资增长战略；对研发的持续投入；对市场和商业领域的深刻认知，使得Angelini Industries成为其运营领域中意大利卓越公司之一。

To learn more visit .

要了解更多信息，请访问。

www.angeliniindustries.com

。

About Blackstone Life Sciences

关于黑石生命科学

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than .

黑石生命科学是一个行业领先的私人投资平台，有能力在关键生命科学领域内的公司和产品的生命周期中进行投资。通过结合大规模投资和亲力亲为的运营领导，黑石生命科学有助于将有前景的新药和医疗技术推向市场，改善患者的生活，目前拥有超过。

$12 billion

120亿美元

in assets under management.

管理的资产。

Corporate Contacts

公司联系人

GRIN Therapeutics

GRIN治疗学

Elliott Ruiz

艾略特·鲁伊斯

, MBA